Press Release

Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

We are delighted that Boehringer Ingelheim has chosen Illumina to be its long-term partner in the development of companion diagnostics for the treatment of cancers

The partnership spans current and future CDx programs, with plans to add CDx claims to an in vitro diagnostic test Illumina is developing that is based on the content of TruSight™ Oncology 500 (TSO 500). The first program will co-develop a CDx for a Boehringer Ingelheim investigational medicine.

"We are delighted that Boehringer Ingelheim has chosen Illumina to be its long-term partner in the development of companion diagnostics for the treatment of cancers," said Joydeep Goswami, Chief Strategy and Corporate Development Officer of Illumina. "Illumina continues to provide the leading distributable assay enabling comprehensive genomic profiling for both tissue and liquid biopsy and together we will unlock the potential of new biomarkers to identify patients most likely to benefit from new precision medicines."

About TruSight Oncology 500
TSO 500 is a Research Use Only comprehensive pan-cancer assay designed to identify 523 known and emerging tumor biomarkers. TSO 500 utilizes both DNA and RNA from tumor samples to identify key variants critical for cancer development and progression, such as small DNA variants, fusions, and splice variants. Based on the content of TSO 500, Illumina will be adding an in vitro diagnostic test to the TruSight Oncology product family. This comprehensive tumor profiling assay will have similar chemistry and analytics to TSO 500. To learn more about TSO 500, click here.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on TwitterFacebookLinkedInInstagram, and YouTube.

Investors:
Salli Schwartz
858.291.6421
IR@illumina.com

Media:
Dr. Karen Birmingham
EMEA: +44 7500 105665
US: 646.355.2111
kbirmingham@illumina.com

 

 

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-and-boehringer-ingelheim-announce-companion-diagnostic-partnership-301456760.html

SOURCE Illumina, Inc.

Recent Articles

Australia’s PrOSPeCT Project Is Sequencing Thousands of Cancer Patients
Australia’s PrOSPeCT Project Is Sequencing Thousands of Cancer Patients
European Customers Share Their Success Stories
Video: European Customers Share Their Success Stories
AI Drives Data Insights for Doctors and their Patients
AI Drives Data Insights for Doctors and their Patients